The Food and Drug Administration approved Rasonque (daraxonrasib), a once-daily targeted therapy by Revolution Medicines, on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma. The drug represents the first in its class for this indication.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
The Food and Drug Administration approved Rasonque, the brand name for Revolution Medicines' daraxonrasib, on Aug. 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy [fda.gov#3][fda.gov#1][fda.gov#2]. The once-daily tablet is the first FDA-approved RAS inhibitor for this disease and tar
The U.S. Food and Drug Administration on Aug. 26 approved Rasonque, also known as daraxonrasib, Revolution Medicines' once-daily pancreatic cancer pill, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or cannot receive multiagent systemic therapy [fda.gov#1][fda.gov#3][abcnews.com#1][arynews.tv#1]. The FDA identified the drug as a RAS inhi
this outlet adds: sold, abc7, tablet, first, targets, multiple, forms, protein